Lestaurtinib, a multitargeted tyrosinse kinase inhibitor: from bench to bedside

Bibliography

• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999:341(14):1051-62
   PubMed Web of Science ®Google Scholar
• Mrózek K, Marcucci G, Paschka P, Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109(2):431-8
   PubMed Web of Science ®Google Scholar
• Schnittger S. FLT3 (FMS-like tyrosine kinase 3). Atlas Genet Cytogenet Oncol Haematol 2005
   Google Scholar
• Rosnet O, Bühring HJ, Marchetto S, Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996;10(2):238-48
   PubMed Web of Science ®Google Scholar
• deLapeyrière O, Naquet P, Planche J, Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation 1995;58(5):351-9
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100(5):1532-42
   PubMed Web of Science ®Google Scholar
• Levis M, Tse KF, Smith BD, A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99(11):3885-91
   PubMed Web of Science ®Google Scholar
• Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000;14(10):1766-76
   PubMed Web of Science ®Google Scholar
• Nakao M, Yokota S, Iwai T, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10(12):1911-8
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352(3):254-66
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Woods WG, Stirewalt DL, Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001;97(1):89-94
   PubMed Web of Science ®Google Scholar
• Bullinger L, Döhner K, Kranz R, An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008;111(9):4490-5
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96(12):3907-14
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99(12):4326-35
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Döhner K, Krauter J, Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358(18):1909-18
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005;19(8):1345-9
   PubMed Web of Science ®Google Scholar
• Mead AJ, Linch DC, Hills RK, FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007;110(4):1262-70
   PubMed Web of Science ®Google Scholar
• Kase H, Iwahashi K, Matsuda Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J Antibiot (Tokyo) 1986;39(8):1059-65
   PubMed Web of Science ®Google Scholar
• Nye SH, Squinto SP, Glass DJ, K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol Biol Cell 1992;3(6):677-86
   PubMed Web of Science ®Google Scholar
• Dionne CA, Camoratto AM, Jani JP, Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 1998;4(8):1887-98
   PubMed Web of Science ®Google Scholar
• Weeraratna AT, Dalrymple SL, Lamb JC, Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 2001;7(8):2237-45
   PubMed Web of Science ®Google Scholar
• Miknyoczki SJ, Chang H, Klein-Szanto A, The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 1999;5(8):2205-12
   PubMed Web of Science ®Google Scholar
• Miknyoczki SJ, Dionne CA, Klein-Szanto AJ, The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann NY Acad Sci 1999;880:252-62
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111(12):5663-71
   PubMed Web of Science ®Google Scholar
• Carow CE, Levenstein M, Kaufmann SH, Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996;87(3):1089-96
   PubMed Web of Science ®Google Scholar
• Brown P, Levis M, Shurtleff S, FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005;105(2):812-20
   PubMed Web of Science ®Google Scholar
• Knapper S, Mills KI, Gilkes AF, The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 2006;108(10):3494-503
   PubMed Web of Science ®Google Scholar
• Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004;104(4):1145-50
   PubMed Web of Science ®Google Scholar
• Mead AJ, Gale RE, Kottaridis PD, Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication. Br J Haematol 2008;141(4):454-60
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009;8(16):2621-30
   PubMed Web of Science ®Google Scholar
• Weisberg E, Roesel J, Bold G, Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood 2008;112(13):5161-70
   PubMed Web of Science ®Google Scholar
• Li L, Piloto O, Kim KT, FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br J Haematol 2007;137(1):64-75
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Womble M, Qiu YH, Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006;108(7):2358-65
   PubMed Web of Science ®Google Scholar
• Mohi MG, Boulton C, Gu TL, Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004;101(9):3130-5
   PubMed Web of Science ®Google Scholar
• Weisberg E, Banerji L, Wright RD, Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood, 2008. 111(7): p. 3723-34
   PubMed Web of Science ®Google Scholar
• Nishioka C, Ikezoe T, Yang J, MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 2008;32(9):1382-92
   PubMed Web of Science ®Google Scholar
• Mollgard L, Deneberg S, Nahi H, The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia. Cancer Chemother Pharmacol 2008;62(3):439-48
   PubMed Web of Science ®Google Scholar
• Kohl TM, Hellinger C, Ahmed F, BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007;21(8):1763-72
   PubMed Web of Science ®Google Scholar
• Fukuda S, Singh P, Moh A, Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood 2009;114(2):394-403
   PubMed Web of Science ®Google Scholar
• Zhou J, Bi C, Janakakumara JV, Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009;113(17):4052-62
   PubMed Web of Science ®Google Scholar
• Weisberg E, Kung AL, Wright RD, Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007;6(7):1951-61
   PubMed Web of Science ®Google Scholar
• Mony U, Jawad M, Seedhouse C, Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. Leukemia 2008;22(7):1395-401
   PubMed Web of Science ®Google Scholar
• Marshall JL, Kindler H, Deeken J, Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 2005;23(1):31-7
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103(10):3669-76
   PubMed Web of Science ®Google Scholar
• Collins C, Carducci MA, Eisenberger MA, Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther 2007:6(9):1360-7
   PubMed Web of Science ®Google Scholar
• Levis M, Brown P, Smith BD, Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006;108(10):3477-83
   PubMed Web of Science ®Google Scholar
• Phase I/II trial of CEP-701 (lestaurtinib) in myelofibrosis
   Google Scholar
• Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythemia vera or essential thrombocytosis
   Google Scholar
• Moliterno AR, Hexner E, Roboz GJ, An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood (ASH Annual Meeting Abstracts), Nov 2009;114:753
   Google Scholar
• Chan E, Mulkerin D, Rothenberg M, A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 2008;26(3):241-7
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108(10):3262-70
   PubMed Web of Science ®Google Scholar
• Levis M, Smith BD, Littlewood T, A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. ASH Annual Meeting Abstracts 2005;106:403
   Google Scholar
• Levis M, Ravandi F, Wang ES, Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse. ASH Annual Meeting Abstracts 2009;114(22):788
   Google Scholar
• AML 17: Working parties on leukaemia in adults and childrentrial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17. Available from: http://aml17.cardiff.ac.uk/files/aml17_protocolv2.pdf
   Google Scholar
• Gotlib J, George TI, Linder A, Phase II trial of the tyrosine kinase inhibitor PKC412 in advanced systemic mastocytosis: preliminary results. ASH Annual Meeting Abstracts 2006;108(11):3609
   Google Scholar
• Stone RM, Fischer T, Paquette R, Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under Age 61. ASH Annual Meeting Abstracts 2006;108(11):157
   Google Scholar
• Phase I/II clinical study of SU11248 (Sutent) combined with standard chemotherapy with cytosine arabinoside and daunorubicin in patients with FLT3 mutated AML over 60 years of age. Available from: www.clinicaltrials.gov
   Google Scholar
• Loges S, Tinnefield H, Metzner J, Treatment of patients with refractory AML with SU5416 downregulates VEGF-A, STAT5 and Akt expression in leukemic blasts. ASH Annual Meeting Abstracts 2005;106(11):2793
   Google Scholar
• Pratz KW, Cortes J, Roboz GJ, A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113(17):3938-46
   PubMed Web of Science ®Google Scholar
• Cortes JE, Ghirdaladze D, Foran JM, Phase 1 AML study of AC220, a potent and selective second generation FLT3 receptor tyrosine kinase inhibitor. ASH Annual Meeting Abstracts 2008;112(11):767
   Google Scholar
• Levis M, Tse KF, Smith BD, A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001;98(3):885-7
   PubMed Web of Science ®Google Scholar
• Tse KF, Allebach J, Levis M, Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002;16(10):2027-36
   PubMed Web of Science ®Google Scholar
• Wong CI, Koh TS, Soo R, Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009;27(28):4718-26
   Google Scholar